Cancer
Vaccines Market, By Type (Preventive and Therapeutic), By Technology
(Subunit Vaccines, Live Attenuated Vaccines, and Others), and By Application
(Cervical Cancer, Prostate Cancer, and Others) - Global Industry Insights,
Trends, Outlook, and Opportunity Analysis, 2018-2026
Cancer is the second leading
cause of morbidity and mortality worldwide. Major cause of cancer is gene
mutation and rarely due to inherited genes. On the basis of the type of cell it
initiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias,
brain tumors, and sarcomas. According to World Health Organization (WHO), 2017,
nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths from
cancer occur in low- and middle-income countries. Moreover, it is projected
that for next two decades, 70% of new cases are expected to be diagnosed
globally. Advent of cancer vaccines can significantly reduce this numbers and
lead a cancer-free life for the global population.
Development of new vaccines for
treatment of different cancers is expected to fuel growth of the cancer
vaccines market over the forecast period
Manufacturers in the cancer
vaccines market are focusing on developing new vaccines in order to treat
various cancers. Through this, they are expected to gain a competitive edge in
the market and increase their market share. For instance, in November 2019, NEC
Corporation and VAXIMM AG, collaborated for the development of novel neoantigen
cancer vaccines.
Also in July 2019, Boehringer
Ingelheim International GmbH., announced the acquisition of AMAL Therapeutics
SA, a company focused development of cancer immunotherapy and cancer vaccines
by its KISIMA technology. The acquisition is expected to enhance Boehringer’s
cancer portfolio and its cancer vaccine platform.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1209
Gilead Science Inc., in 2017,
acquired Kite Pharma Inc., which is involved in development of different type
of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with
Pharmaceutical Product Development, LLC (PPD), in order to conduct its
first-in-human clinical trial for its cancer vaccine for metastatic colorectal
cancer.
Furthermore, BioNTech developed
RNA vaccines for mutations caused due to cancer. RNA vaccine exposes cancer
cell to antigen, which is recognized by the immune system. On the other hand,
Scancell’s DNA vaccine forces cancerous cell to express two antigens – gp100
and TRP-2 stimulating a strong T cell response.
In 2017, Jonsson Comprehensive
Cancer Center and the Brain Tumor Center at the University of California Los
Angeles (UCLA), was designated a Specialized Program of Research Excellence
(SPORE) by the National Cancer Institute. The program is expected to support
research into prevention, detection, and treatment of cancers and will promote
co-operation among scientist in different disciplines, and also help to
translate basic research from laboratories to clinical trials more quickly and
effectively. Such recognition by national organizations is expected to support
research in cancer vaccines.
According to a research from
University of Pittsburgh School of Medicine, in 2017, a high dose flu vaccine
can be used to treat people aged between 54–64 years with chronic condition
such as heart disease, lung disease, diabetes, and cancer. The study is recommended
for clinical trials in geriatric population.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/cancer-vaccines-market-1209
Also, in 2017, Swiss Biotech,
developed VXM01 — an attenuated bacterial vaccine modified to express vascular
endothelial growth factor receptor-2 (VEGFR2), stimulates cytotoxic (killer) T
cells, which will destroy cells in the vasculature feeding tumor and allow
greater infiltration of immune cells. This vaccine is expected to be used for
treatment in colorectal cancer and glioblastoma.
In August 2017, Imugene Limited
announced the entry of its anti-cancer vaccine, HER-Vaxx for gastric cancer in
1b/2 clinical study and the phase 2 is expected to start soon.
Increasing prevalence and
incidence of different cancers is expected to favor growth of the cancer
vaccines market
According to WHO, in 2015, about
8.8 million people died from cancer. Moreover, tobacco related cancers was
responsible for 22% deaths, lung cancer accounted for 1.69 million deaths,
liver cancer led to 788,000 deaths. Colorectal, stomach, and breast cancer are
estimated to cause 774,000, 754,000, and 571,000 deaths, worldwide. Increasing
prevalence is a major driving factor to fuel growth of the cancer vaccines
market.
According to the American Cancer
Society, 2017, cancer is the second most common cause of death in the U.S.,
which accounts for nearly 1 out of every 4 deaths.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1209
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment